Standard Dose of Biktarvy for HIV-1 Treatment

Dosing Considerations

The standard dose of Biktarvy for the treatment of HIV-1 infection is one tablet containing bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, taken orally once daily with or without food, as recommended by the American Medical Association 1, 2
Biktarvy is a complete single-tablet regimen that does not require additional antiretroviral agents for HIV-1 treatment, providing a simple and effective treatment option 2
The medication can be taken with or without food, providing flexibility for patients, according to the Centers for Disease Control and Prevention 2
Biktarvy has relatively few drug interactions compared to other antiretroviral regimens, making it a convenient option for patients with multiple medications 2

Important interaction to note: Biktarvy cannot be used with rifampin, which is a significant consideration for patients requiring tuberculosis treatment, as advised by the World Health Organization 2
For patients with latent tuberculosis infection receiving once-weekly isoniazid and rifapentine (3HP), data suggest that bictegravir-containing regimens might be considered if dolutegravir-containing regimens cannot be used, according to the National Institutes of Health 3, 4
For patients with active tuberculosis on rifampin-containing regimens, limited data suggest twice-daily dosing of BIC/TAF/FTC may maintain viral suppression, as reported by the Journal of the American Medical Association 5

Not considering potential drug interactions, particularly with medications containing polyvalent cations (calcium, iron, magnesium, aluminum) which can reduce bictegravir absorption, as warned by the Food and Drug Administration 2
Confusing Biktarvy dosing with other integrase inhibitor regimens that may require twice-daily dosing or food requirements, which can lead to treatment failure, as cautioned by the American College of Physicians 2

Biktarvy can be taken with or without food, offering a key advantage over many other antiretroviral regimens that require meals for optimal absorption. 6
The regimen provides complete dosing flexibility regardless of meal timing or caloric intake, distinguishing it from elvitegravir/cobicistat‑based therapies that must be taken with food. 6

Clinicians should not mistake Biktarvy’s food‑independent dosing for that of elvitegravir‑based regimens, which require food to achieve adequate drug exposure. 6